Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Editas Medicine (EDIT)

$25.50 0.59 (2.26%)

16:32 EDT EDIT Stock Quote Delayed 15 Minutes

Volume:

Previous Close $25.50

Market Cap 1.21B

PE Ratio -9.11

EPS -2.8

Volume (Avg. Vol.) 624,700

Day's Range 25.42 - 26.62

52-Week Range 17.80 - 33.80

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

From InvestorPlace
From the Web

3 Biotech Stocks That Are Set for a Breakthrough

By Matt McCall, Editor, MoneyWire Feb 1, 2019

If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.

Gene Editing is a Major Technology to Watch

By Matt McCall, Editor, MoneyWire Aug 27, 2018

Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.

Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings

By Fintel May 31, 2017

13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks

Adverum Reports Data From Phase I Wet AMD Study, Stock Down

From Zacks Investment Research Sep 13, 2019

Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.

ETFs Poised to Benefit from Gene Editing Revolution

From Zacks Investment Research Sep 6, 2019

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?

From Zacks Investment Research Sep 5, 2019

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EDIT Makes Notable Cross Below Critical Moving Average

From Market News Video Sep 3, 2019

In trading on Tuesday, shares of Editas Medicine Inc (EDIT) crossed below their 200 day moving average of $24.19, changing hands as low as $23.91 per share. Editas Medicine Inc shares are currently trading down about 3.5% on the day..

The CEO, President & Director of Editas Medicine, Inc. (NASDAQ:EDIT), Cynthia Collins, Just Sold 31.3% Of Their Holding

From Simply Wall St Aug 28, 2019

We’d be surprised if Editas Medicine, Inc. (NASDAQ:EDIT) shareholders haven’t noticed that the CEO, President & Director, Cynthia Collins, recently sold US$134k worth of stock at US$25.83 per share. The<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/the-ceo-president-director-of-editas-medicine-inc-nasdaqedit-cynthia-collins-just-sold-31-3-of-their-holding/">Read More...</a></div>

Your Digital Self: CRISPR gene-editing technique set to push new boundaries

From Marketwatch Aug 27, 2019

Biotechnology companies are seeking to cure forms of blindness, muscular dystrophy and leukemia.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!